Nami Surgical Secures Investment to Transform Robotic-Assisted Surgery Market
08 Mayo 2024 - 8:05AM
Business Wire
Nami Surgical, which is aiming to transform the robotic-assisted
surgery market with a breakthrough ultrasonic platform, has secured
$4 million of investment and grant funding. St Andrews-based impact
investment firm Eos Advisory (Eos) led the seed $3.1 million round
alongside the Investment Fund for Scotland, which is managed by UK
private equity firm Maven and delivered by British Business Bank,
Scottish Enterprise, and SIS Ventures, while the company was
separately awarded a grant from Innovate UK, the United Kingdom’s
national innovation agency.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240508013293/en/
Nami Surgical's Nico Fenu (CEO and
Co-founder) and Dr Rebecca Cleary (CTO and Co-founder) (Photo:
Business Wire)
Nami Surgical develops miniaturised ultrasonic medical devices
for surgical applications, and supports medical device companies to
deliver innovation in ultrasonic surgery. In a groundbreaking
development, Nami has introduced a high-performance, miniaturised
ultrasonic scalpel, overcoming significant barriers in
robotic-assisted surgery. Traditionally favoured in laparoscopic
procedures, ultrasonic scalpels have been too large for effective
use in robotic surgery until now.
Robotic surgeries, characterised by enhancing surgical precision
and dexterity, significantly reduce patient trauma, post-operative
pain, and recovery times, leading to shorter hospital stays. As
robotic surgery becomes the standard for various procedures, its
global market is set to quadruple, reaching approximately $36
billion by 2032. With Nami’s pioneering technology, the integration
of ultrasonic scalpels in robotic surgeries sets a new benchmark in
surgical care, promising improved outcomes for patients
worldwide.
Nami Surgical’s CEO and Co-founder Nico Fenu said:
“Robot-assisted surgery has become increasingly popular in recent
years and is now widely used in various surgical procedures
including urology, gynaecology, and colorectal. We have pilot
programmes running with healthcare and medical device groups
worldwide, including in the United States, and we now look forward
to the commercialisation phase with the support of our new
investors.”
The company was co-founded by CTO Dr Rebecca Cleary in 2022 and
is chaired by experienced life science and medtech NXD Albert
Nicholl. Albert Nicholl said: “We have a huge opportunity ahead of
us, and a fast route to market with the first product from the
platform.”
Nico Fenu added: “We are committed to close collaboration with
clinicians and companies in the industry to translate their needs
into novel devices that not only improve patient outcomes, but also
drive ultrasonic surgery to the next level. It's an exciting time
for us, and we are just getting started.”
For more information: https://www.namisurgical.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240508013293/en/
Media contact: Nick Freer nick@freerconsultancy.com